Ignite Creation Date:
2024-05-06 @ 3:47 PM
Last Modification Date:
2024-10-26 @ 1:56 PM
Study NCT ID:
NCT04750382
Status:
UNKNOWN
Last Update Posted:
2021-02-11
First Post:
2021-02-08
Brief Title:
A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer
Sponsor:
Taizhou Hanzhong biomedical co LTD
Organization:
Taizhou Hanzhong biomedical co LTD
Study Overview
Official Title:
A Single-armed Multicenter Phase Ib II Study of HX008 a Recombinant Humanized Anti-PD-1 Monoclonal Antibody Combined With GP Regimen as the First-line Treatment in Patients With Metastatic Triple Negative Breast Cancer
Status:
UNKNOWN
Status Verified Date:
2021-02
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
HX008 is a humanized monoclonal antibody targeting PD-1 on T cell surface restores T cell activity thus enhancing immune response and has potential to treat various types of tumors In this study the safety and preliminary efficacy of HX008cisplatingemcitabine for the treatment of patients with metastatic triple-negative breast cancer will be evaluated
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None